Free Trial
NASDAQ:BNBX

Applied Dna Sciences Q3 2026 Earnings Results & Report

Applied Dna Sciences logo
$0.09 0.00 (0.00%)
As of 11/13/2026 11:30 AM Eastern

Applied Dna Sciences reported Q3 2026 earnings on August 13, 2026. The company reported EPS of -$0.57, while revenue was $605.31 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes

Applied Dna Sciences EPS Results

Actual EPS
-$0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Applied Dna Sciences Revenue Results

Actual Revenue
$605.31 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Applied Dna Sciences Q3 2026 Earnings FAQ

Applied Dna Sciences (NASDAQ:BNBX) reported earnings of -$0.57 per share for Q3 2026. The report was announced on Thursday, August 13, 2026.

Applied Dna Sciences reported revenue of $605.31 thousand for Q3 2026.

Applied Dna Sciences Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Applied Dna Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Dna Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Dna Sciences and other key companies, straight to your email.

About Applied Dna Sciences

Applied Dna Sciences (NASDAQ:BNBX), Inc. is a biotechnology company that develops DNA-based technologies for molecular diagnostics, therapeutics and industrial applications. Its platform is designed to produce and analyze DNA for use in areas including infectious disease testing, genetic medicine and product authentication.

The company has also developed DNA-based supply-chain and anti-counterfeiting solutions, including technologies intended to help authenticate textiles, pharmaceutical products and other goods. Applied DNA Sciences has served commercial, healthcare and government-related customers, primarily in the United States, while pursuing additional international applications for its technologies.

Applied DNA Sciences is generally identified by the Nasdaq ticker APDN; the ticker BNBX does not appear to correspond to the company. The company was founded in 2003 and has historically been led by Chief Executive Officer James A. Hayward.

View Applied Dna Sciences Profile